Zhipeng Wang, Hongsen Wang, Chen Bu, Bosu Meng, Yuhui Mu, Shouhong Gao, Wansheng Chen, Xia Tao
INTRODUCTION: Since the first experimentally proven tyrosine kinase inhibitor (TKI) imatinib was introduced in the clinical setting, TKIs have attracted widespread attention because of their remarkable therapeutic effects and improvement of survival rates. TKIs are small-molecule, multi-target, anti-cancer agents that target different tyrosine kinases and block downstream signaling. ADVERSE REACTIONS AND CONCERNS: However, with in-depth research on TKI drugs, the adverse reactions-for example, thyroid dysfunction-have become a concern and thus have attracted the attention of numerous researchers...
March 14, 2024: European Journal of Clinical Pharmacology